[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100365292":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":19,"locations":28,"responsibleParty":46,"collaborators":7,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":7,"studyType":63,"phases":7,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",null,[9,12,15,17],{"name":10,"affiliation":5,"role":11},"Maria Del Ben, MD","STUDY_DIRECTOR",{"name":13,"affiliation":5,"role":14},"Daniele Pastori, MD","PRINCIPAL_INVESTIGATOR",{"name":16,"affiliation":5,"role":14},"Francesco Baratta, MD",{"name":18,"affiliation":5,"role":14},"Francesco Angelico, MD",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Francesco Baratta, MD, PI.","CONTACT","+390649972249","francesco.baratta@uniroma1.it",{"name":26,"role":22,"phone":23,"phoneExt":7,"email":27},"Daniele Pastori, MD, PI.","daniele.pastori@uniroma1.it",[29],{"facility":30,"status":31,"city":32,"state":7,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Day Service of Internal Medicine and Metabolic Disorders - Policlinico Umberto I - Sapienza University of Rome","RECRUITING","Rome","00100","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],12.51133,41.89193,{"lat":40,"lon":39},[43,45],{"name":10,"role":22,"phone":23,"phoneExt":7,"email":44},"maria.delben@uniroma1.it",{"name":16,"role":22,"phone":23,"phoneExt":7,"email":24},{"type":14,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Francesco Violi","Department Head","100365292","liver-damage-and-cardiometabolic-disorders-in-nafld-100365292",false,"NCT04036357","Liver Damage and Cardiometabolic Disorders in NAFLD","Progression of LIver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver dIsease: an Observational Cohort STUDY. The Plinio Study","PLINIO","Inclusion Criteria:\n\n* Patients aged 18 years old or more\n* Patients with at least on of the following metabolic disorders\n\n  * Obesity\n  * Diabetes\n  * Arterial hypertension\n  * Dyslipidemia\n\nExclusion Criteria:\n\n* Average daily consumption of alcohol \\>20 g in women and of \\>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT;\n* presence of hepatitis B surface antigen and antibody to hepatitis C virus;\n* positive tests for autoimmune hepatitis;\n* cirrhosis and other chronic liver diseases;\n* diagnosis of oncological diseases\n* concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone);\n* other chronic infectious or autoimmune disease;","ALL","18 Years","80 Years",{"count":61,"type":62},2000,"ESTIMATED","OBSERVATIONAL","Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.",[66,67,68,69],"NAFLD","Liver Fibroses","Cardiovascular Diseases","Cardiovascular Risk Factor",[66,71,72],"Liver fibrosis","Cardiovascular","2019-08-13",{"date":75,"type":76},"2019-08-16","ACTUAL",{"date":78,"type":76},"2011-11",{"date":80,"type":62},"2036-12-31",{"name":5,"class":6},1]